Century Therapeutics Inc (IPSC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $299.63M
Last updated: Nov 17, 2026 at 11:06 AM ET
Century Therapeutics Inc (IPSC) Stock Forecast
Analysts expect Century Therapeutics (IPSC) to earn -$0.47 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 3 | 60.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.47
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.45
- EPS consensus
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.47 | -$0.52 to -$0.37 | 3 |
| Dec 31, 2027 | -$0.45 | -$0.55 to -$0.28 | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.14 to -$0.13 | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.46.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.47 | -$0.47 | -$0.47 | -$0.45 | -$0.46 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.45 | -$0.45 | -$0.45 | -$0.46 | -$0.46 | N/A |
Frequently Asked Questions About IPSC
What is the IPSC stock forecast?
Consensus analyst estimates put Century Therapeutics's EPS at -$0.47 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Buy.
How do analysts rate IPSC stock?
Of 5 analysts covering Century Therapeutics, 1 rates it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IPSC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.47, with estimates from -$0.52 to -$0.37 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.45, with estimates from -$0.55 to -$0.28 from 4 analysts.
How many analysts cover IPSC?
5 analysts rate Century Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IPSC pages: Overview, Earnings, Forecast, Financials, Competitors